BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 38527740)

  • 21. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methods for Evaluating the Efficacy of Medical Castration: A Systematic Review.
    Aguilar A; Planas J; Trilla E; Morote J
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
    Shore ND; Morgans AK; Ryan CJ
    Clin Genitourin Cancer; 2021 Jun; 19(3):199-207. PubMed ID: 33129718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
    Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
    Eur Urol; 2023 Mar; 83(3):267-293. PubMed ID: 36494221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers.
    Saad F; Hotte SJ; Finelli A; Malone S; Niazi T; Noonan K; Shayegan B; So AI; Danielson B; Basappa NS; Cagiannos I; Canil C; Delouya G; Fernandes R; Ferrario C; Gotto GT; Hamilton RJ; Izard JP; Kapoor A; Khalaf D; Kolinsky M; Lalani AK; Lavallée LT; Morash C; Morgan SC; Ong M; Pouliot F; Rendon RA; Yip S; Zardan A; Park-Wyllie L; Chi K
    Can Urol Assoc J; 2021 Oct; 15(10):353-358. PubMed ID: 34125066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting.
    Pejčić T; Todorović Z; Đurašević S; Popović L
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prostate cancer. Treatment].
    Fournier G; Valeri A; Mangin P; Cussenot O
    Ann Urol (Paris); 2004 Oct; 38(5):225-58. PubMed ID: 15570706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.
    Sheehan B; Guo C; Neeb A; Paschalis A; Sandhu S; de Bono JS
    Eur Urol Focus; 2022 Sep; 8(5):1157-1168. PubMed ID: 34167925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design.
    van den Bos W; Muller BG; Ahmed H; Bangma CH; Barret E; Crouzet S; Eggener SE; Gill IS; Joniau S; Kovacs G; Pahernik S; de la Rosette JJ; Rouvière O; Salomon G; Ward JF; Scardino PT
    Eur Urol; 2014 Jun; 65(6):1078-83. PubMed ID: 24444476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?
    Caffo O; Maines F; Kinspergher S; Veccia A; Messina C
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):389-400. PubMed ID: 33245666
    [No Abstract]   [Full Text] [Related]  

  • 34. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
    Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions.
    Kucera R; Pecen L; Topolcan O; Dahal AR; Costigliola V; Giordano FA; Golubnitschaja O
    EPMA J; 2020 Sep; 11(3):399-418. PubMed ID: 32843909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chinese expert consensus on the follow-up management of patients with prostate cancer receiving medical castration therapy(2024 edition)].
    Chinese Prostate Cancer Consortium
    Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(0):285-295. PubMed ID: 38527740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review.
    Kretschmer A; Ploussard G; Heidegger I; Tsaur I; Borgmann H; Surcel C; Mathieu R; de Visschere P; Valerio M; van den Bergh RCN; Marra G; Thibault C; Ost P; Gandaglia G; Tilki D;
    Eur Urol Focus; 2021 Jul; 7(4):742-751. PubMed ID: 32089495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    Giri VN; Knudsen KE; Kelly WK; Abida W; Andriole GL; Bangma CH; Bekelman JE; Benson MC; Blanco A; Burnett A; Catalona WJ; Cooney KA; Cooperberg M; Crawford DE; Den RB; Dicker AP; Eggener S; Fleshner N; Freedman ML; Hamdy FC; Hoffman-Censits J; Hurwitz MD; Hyatt C; Isaacs WB; Kane CJ; Kantoff P; Karnes RJ; Karsh LI; Klein EA; Lin DW; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann MJ; Mark JR; McCue PA; Miner MM; Morgan T; Moul JW; Myers RE; Nielsen SM; Obeid E; Pavlovich CP; Peiper SC; Penson DF; Petrylak D; Pettaway CA; Pilarski R; Pinto PA; Poage W; Raj GV; Rebbeck TR; Robson ME; Rosenberg MT; Sandler H; Sartor O; Schaeffer E; Schwartz GF; Shahin MS; Shore ND; Shuch B; Soule HR; Tomlins SA; Trabulsi EJ; Uzzo R; Vander Griend DJ; Walsh PC; Weil CJ; Wender R; Gomella LG
    J Clin Oncol; 2018 Feb; 36(4):414-424. PubMed ID: 29236593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 2.